Published in J Biol Chem on February 10, 2010
Structure of an agonist-bound human A2A adenosine receptor. Science (2011) 6.21
Biased signaling pathways in β2-adrenergic receptor characterized by 19F-NMR. Science (2012) 3.07
Diversity and modularity of G protein-coupled receptor structures. Trends Pharmacol Sci (2011) 2.89
Status of GPCR modeling and docking as reflected by community-wide GPCR Dock 2010 assessment. Structure (2011) 2.11
The GPCR Network: a large-scale collaboration to determine human GPCR structure and function. Nat Rev Drug Discov (2012) 1.50
Structure based prediction of subtype-selectivity for adenosine receptor antagonists. Neuropharmacology (2010) 1.31
Structure-guided design of A(3) adenosine receptor-selective nucleosides: combination of 2-arylethynyl and bicyclo[3.1.0]hexane substitutions. J Med Chem (2012) 1.23
Biophysical mapping of the adenosine A2A receptor. J Med Chem (2011) 1.08
Ligand-dependent activation and deactivation of the human adenosine A(2A) receptor. J Am Chem Soc (2013) 1.02
G protein-coupled adenosine (P1) and P2Y receptors: ligand design and receptor interactions. Purinergic Signal (2012) 1.00
Molecular Determinants of CGS21680 Binding to the Human Adenosine A2A Receptor. Mol Pharmacol (2015) 0.96
Evaluation of molecular modeling of agonist binding in light of the crystallographic structure of an agonist-bound A₂A adenosine receptor. J Med Chem (2011) 0.96
Agonist dynamics and conformational selection during microsecond simulations of the A(2A) adenosine receptor. Biophys J (2012) 0.96
GPCR agonist binding revealed by modeling and crystallography. Trends Pharmacol Sci (2011) 0.93
Optimization of adenosine 5'-carboxamide derivatives as adenosine receptor agonists using structure-based ligand design and fragment screening. J Med Chem (2012) 0.93
Analysis of adenosine A₂a receptor stability: effects of ligands and disulfide bonds. Biochemistry (2010) 0.89
Structural and energetic effects of A2A adenosine receptor mutations on agonist and antagonist binding. PLoS One (2014) 0.82
Chemogenomic analysis of G-protein coupled receptors and their ligands deciphers locks and keys governing diverse aspects of signalling. PLoS One (2011) 0.81
Structure-activity relationships and molecular modeling of 1,2,4-triazoles as adenosine receptor antagonists. ACS Med Chem Lett (2012) 0.79
Homology model and docking studies on porcine β₂ adrenoceptor: description of two binding sites. J Mol Model (2011) 0.79
Role of extracellular cysteine residues in the adenosine A2A receptor. Purinergic Signal (2016) 0.78
Three "hotspots" important for adenosine A(2B) receptor activation: a mutational analysis of transmembrane domains 4 and 5 and the second extracellular loop. Purinergic Signal (2011) 0.77
Conserved disulfide bond is not essential for the adenosine A2A receptor: Extracellular cysteines influence receptor distribution within the cell and ligand-binding recognition. Biochim Biophys Acta (2014) 0.77
Homology models of melatonin receptors: challenges and recent advances. Int J Mol Sci (2013) 0.76
Expression, Purification, and Monitoring of Conformational Changes of hCB2 TMH67H8 in Different Membrane-Mimetic Lipid Mixtures Using Circular Dichroism and NMR Techniques. Membranes (Basel) (2017) 0.75
Discovery of 3,4-Dihydropyrimidin-2(1H)-ones As a Novel Class of Potent and Selective A2B Adenosine Receptor Antagonists. ACS Med Chem Lett (2013) 0.75
Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction. Biochem Pharmacol (1973) 47.81
The 2.6 angstrom crystal structure of a human A2A adenosine receptor bound to an antagonist. Science (2008) 11.74
International Union of Pharmacology. XXV. Nomenclature and classification of adenosine receptors. Pharmacol Rev (2001) 9.90
Community-wide assessment of GPCR structure modelling and ligand docking: GPCR Dock 2008. Nat Rev Drug Discov (2009) 2.23
Actions of adenosine at its receptors in the CNS: insights from knockouts and drugs. Annu Rev Pharmacol Toxicol (2005) 2.19
Discovery of new GPCR biology: one receptor structure at a time. Structure (2009) 2.08
Analysis of full and partial agonists binding to beta2-adrenergic receptor suggests a role of transmembrane helix V in agonist-specific conformational changes. J Mol Recognit (2009) 2.05
Site-directed mutagenesis identifies residues involved in ligand recognition in the human A2a adenosine receptor. J Biol Chem (1995) 1.92
Structure-based discovery of novel chemotypes for adenosine A(2A) receptor antagonists. J Med Chem (2010) 1.88
2-Amino-6-furan-2-yl-4-substituted nicotinonitriles as A2A adenosine receptor antagonists. J Med Chem (2008) 1.87
Modeling the adenosine receptors: comparison of the binding domains of A2A agonists and antagonists. J Med Chem (2003) 1.70
Glutamate residues in the second extracellular loop of the human A2a adenosine receptor are required for ligand recognition. Mol Pharmacol (1996) 1.54
Mutagenesis reveals structure-activity parallels between human A2A adenosine receptors and biogenic amine G protein-coupled receptors. J Med Chem (1997) 1.51
Evaluation of homology modeling of G-protein-coupled receptors in light of the A(2A) adenosine receptor crystallographic structure. J Med Chem (2009) 1.38
Hydrophilic side chains in the third and seventh transmembrane helical domains of human A2A adenosine receptors are required for ligand recognition. Mol Pharmacol (1996) 1.33
Site-directed mutagenesis studies of human A(2A) adenosine receptors: involvement of glu(13) and his(278) in ligand binding and sodium modulation. Biochem Pharmacol (2000) 1.11
The flexible pocketome engine for structural chemogenomics. Methods Mol Biol (2009) 1.11
Molecular modeling of adenosine receptors: new results and trends. Med Res Rev (2008) 1.04
Profiling of membrane protein variants in a baculovirus system by coupling cell-surface detection with small-scale parallel expression. Protein Expr Purif (2007) 1.01
Molecular modeling of A1 and A2A adenosine receptors: comparison of rhodopsin- and beta2-adrenergic-based homology models through the docking studies. J Comput Chem (2009) 0.95
5'-N-substituted carboxamidoadenosines as agonists for adenosine receptors. J Med Chem (1999) 0.88
High-resolution crystal structure of an engineered human beta2-adrenergic G protein-coupled receptor. Science (2007) 20.32
GPCR engineering yields high-resolution structural insights into beta2-adrenergic receptor function. Science (2007) 11.74
The 2.6 angstrom crystal structure of a human A2A adenosine receptor bound to an antagonist. Science (2008) 11.74
Structures of the CXCR4 chemokine GPCR with small-molecule and cyclic peptide antagonists. Science (2010) 10.30
Structure of an agonist-bound human A2A adenosine receptor. Science (2011) 6.21
A specific cholesterol binding site is established by the 2.8 A structure of the human beta2-adrenergic receptor. Structure (2008) 6.01
Structural genomics of the Thermotoga maritima proteome implemented in a high-throughput structure determination pipeline. Proc Natl Acad Sci U S A (2002) 6.00
Structure of the human dopamine D3 receptor in complex with a D2/D3 selective antagonist. Science (2010) 5.86
Structure of the human κ-opioid receptor in complex with JDTic. Nature (2012) 5.18
Structure-function of the G protein-coupled receptor superfamily. Annu Rev Pharmacol Toxicol (2012) 3.83
Crystal structure of a lipid G protein-coupled receptor. Science (2012) 3.78
Serial femtosecond crystallography of G protein-coupled receptors. Science (2013) 3.58
Structure of the human histamine H1 receptor complex with doxepin. Nature (2011) 3.48
Structural basis for allosteric regulation of GPCRs by sodium ions. Science (2012) 3.40
Structure of the CCR5 chemokine receptor-HIV entry inhibitor maraviroc complex. Science (2013) 3.17
Structure of the human smoothened receptor bound to an antitumour agent. Nature (2013) 3.08
Biased signaling pathways in β2-adrenergic receptor characterized by 19F-NMR. Science (2012) 3.07
Structure of the nociceptin/orphanin FQ receptor in complex with a peptide mimetic. Nature (2012) 2.96
Microscale fluorescent thermal stability assay for membrane proteins. Structure (2008) 2.95
Diversity and modularity of G protein-coupled receptor structures. Trends Pharmacol Sci (2011) 2.89
Structure of the human glucagon class B G-protein-coupled receptor. Nature (2013) 2.86
Discovery and characterization of a highly selective FAAH inhibitor that reduces inflammatory pain. Chem Biol (2009) 2.82
Rastering strategy for screening and centring of microcrystal samples of human membrane proteins with a sub-10 microm size X-ray synchrotron beam. J R Soc Interface (2009) 2.69
Molecular evolution of antibody cross-reactivity for two subtypes of type A botulinum neurotoxin. Nat Biotechnol (2006) 2.66
Conserved binding mode of human beta2 adrenergic receptor inverse agonists and antagonist revealed by X-ray crystallography. J Am Chem Soc (2010) 2.62
Structural features for functional selectivity at serotonin receptors. Science (2013) 2.60
Structural basis of severe acute respiratory syndrome coronavirus ADP-ribose-1''-phosphate dephosphorylation by a conserved domain of nsP3. Structure (2005) 2.55
Structural adaptations in a membrane enzyme that terminates endocannabinoid signaling. Science (2002) 2.50
Crystal structure of the anti-viral APOBEC3G catalytic domain and functional implications. Nature (2008) 2.36
Severe acute respiratory syndrome coronavirus papain-like protease: structure of a viral deubiquitinating enzyme. Proc Natl Acad Sci U S A (2006) 2.28
Community-wide assessment of GPCR structure modelling and ligand docking: GPCR Dock 2008. Nat Rev Drug Discov (2009) 2.23
Status of GPCR modeling and docking as reflected by community-wide GPCR Dock 2010 assessment. Structure (2011) 2.11
Fusion partner toolchest for the stabilization and crystallization of G protein-coupled receptors. Structure (2012) 2.08
Discovery of new GPCR biology: one receptor structure at a time. Structure (2009) 2.08
Automated sample mounting and alignment system for biological crystallography at a synchrotron source. Structure (2004) 2.00
Structural basis of cell surface receptor recognition by botulinum neurotoxin B. Nature (2006) 1.97
Shotgun crystallization strategy for structural genomics: an optimized two-tiered crystallization screen against the Thermotoga maritima proteome. Acta Crystallogr D Biol Crystallogr (2003) 1.92
An efficient, versatile and scalable pattern growth approach to mine frequent patterns in unaligned protein sequences. Bioinformatics (2007) 1.92
Structure-based discovery of novel chemotypes for adenosine A(2A) receptor antagonists. J Med Chem (2010) 1.88
2-Amino-6-furan-2-yl-4-substituted nicotinonitriles as A2A adenosine receptor antagonists. J Med Chem (2008) 1.87
Structural basis for molecular recognition at serotonin receptors. Science (2013) 1.86
Genetically encoded chemical probes in cells reveal the binding path of urocortin-I to CRF class B GPCR. Cell (2013) 1.83
Structure of a class C GPCR metabotropic glutamate receptor 1 bound to an allosteric modulator. Science (2014) 1.81
Rapid refinement of crystallographic protein construct definition employing enhanced hydrogen/deuterium exchange MS. Proc Natl Acad Sci U S A (2004) 1.70
Stabilization of the human beta2-adrenergic receptor TM4-TM3-TM5 helix interface by mutagenesis of Glu122(3.41), a critical residue in GPCR structure. J Mol Biol (2007) 1.63
A structural perspective of the sequence variability within botulinum neurotoxin subtypes A1-A4. J Mol Biol (2006) 1.59
Three-dimensional structure of human tryptophan hydroxylase and its implications for the biosynthesis of the neurotransmitters serotonin and melatonin. Biochemistry (2002) 1.59
Structural basis for modulation of a G-protein-coupled receptor by allosteric drugs. Nature (2013) 1.59
Designing facial amphiphiles for the stabilization of integral membrane proteins. Angew Chem Int Ed Engl (2007) 1.55
Ligand-dependent perturbation of the conformational ensemble for the GPCR β2 adrenergic receptor revealed by HDX. Structure (2011) 1.54
Crystal structure of botulinum neurotoxin type A in complex with the cell surface co-receptor GT1b-insight into the toxin-neuron interaction. PLoS Pathog (2008) 1.54
Multi-RELIEF: a method to recognize specificity determining residues from multiple sequence alignments using a Machine-Learning approach for feature weighting. Bioinformatics (2007) 1.51
Crystal structure of TM1367 from Thermotoga maritima at 1.90 A resolution reveals an atypical member of the cyclophilin (peptidylprolyl isomerase) fold. Proteins (2006) 1.51
The GPCR Network: a large-scale collaboration to determine human GPCR structure and function. Nat Rev Drug Discov (2012) 1.50
Identifying conformational changes of the beta(2) adrenoceptor that enable accurate prediction of ligand/receptor interactions and screening for GPCR modulators. J Comput Aided Mol Des (2009) 1.48
Structural plasticity and the evolution of antibody affinity and specificity. J Mol Biol (2003) 1.47
Crystal structure of thy1, a thymidylate synthase complementing protein from Thermotoga maritima at 2.25 A resolution. Proteins (2002) 1.45
Time-controlled microfluidic seeding in nL-volume droplets to separate nucleation and growth stages of protein crystallization. Angew Chem Int Ed Engl (2006) 1.45
Lung ischemia-reperfusion injury: a molecular and clinical view on a complex pathophysiological process. Am J Physiol Heart Circ Physiol (2010) 1.43
In situ data collection and structure refinement from microcapillary protein crystallization. J Appl Crystallogr (2005) 1.42
Structure-guided inhibitor design for human FAAH by interspecies active site conversion. Proc Natl Acad Sci U S A (2008) 1.41
Protein biophysical properties that correlate with crystallization success in Thermotoga maritima: maximum clustering strategy for structural genomics. J Mol Biol (2004) 1.40
The crystal structure of the α-neurexin-1 extracellular region reveals a hinge point for mediating synaptic adhesion and function. Structure (2011) 1.39
Dynamics of the beta2-adrenergic G-protein coupled receptor revealed by hydrogen-deuterium exchange. Anal Chem (2010) 1.38
Crystal structure and DNA binding of the homeodomain of the stem cell transcription factor Nanog. J Mol Biol (2007) 1.35
The structure of a eukaryotic nicotinic acid phosphoribosyltransferase reveals structural heterogeneity among type II PRTases. Structure (2005) 1.33
In situ X-ray analysis of protein crystals in low-birefringent and X-ray transmissive plastic microchannels. Acta Crystallogr D Biol Crystallogr (2008) 1.32
Crystal structure-based virtual screening for fragment-like ligands of the human histamine H(1) receptor. J Med Chem (2011) 1.30
Crystallization data mining in structural genomics: using positive and negative results to optimize protein crystallization screens. Methods (2004) 1.30
Correction of kinetic and stability defects by tetrahydrobiopterin in phenylketonuria patients with certain phenylalanine hydroxylase mutations. Proc Natl Acad Sci U S A (2004) 1.28
G protein-coupled receptor heteromerization: a role in allosteric modulation of ligand binding. Mol Pharmacol (2011) 1.27
Recent progress in the structure determination of GPCRs, a membrane protein family with high potential as pharmaceutical targets. Methods Mol Biol (2010) 1.27
Proteomics analysis unravels the functional repertoire of coronavirus nonstructural protein 3. J Virol (2008) 1.27
In meso crystal structure and docking simulations suggest an alternative proteoglycan binding site in the OpcA outer membrane adhesin. Proteins (2008) 1.26
Crystal structure of nonstructural protein 10 from the severe acute respiratory syndrome coronavirus reveals a novel fold with two zinc-binding motifs. J Virol (2006) 1.24
High resolution structure of the ba3 cytochrome c oxidase from Thermus thermophilus in a lipidic environment. PLoS One (2011) 1.23